Summit Therapeutics (SMMT) 주식 개요
서밋 테라퓨틱스는 바이오 제약 회사로 환자, 의사, 간병인 및 사회 친화적인 의학적 치료법의 발견, 개발 및 상용화에 주력하고 있습니다. 자세히 보기
SMMT Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Summit Therapeutics Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$17.89 |
| 52주 최고가 | US$30.98 |
| 52주 최저가 | US$13.83 |
| 베타 | -1.26 |
| 1개월 변동 | -28.78% |
| 3개월 변동 | 12.73% |
| 1년 변동 | -29.59% |
| 3년 변동 | 940.12% |
| 5년 변동 | 118.97% |
| IPO 이후 변동 | 73.86% |
최근 뉴스 및 업데이트
Seeking Alpha • May 04
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary
Summary Summit Therapeutics Inc. continues its march toward potential approval in lung cancer. Recent updates put the utility of ivonescimab into question as a frontline therapy. This article is going to focus on explaining what this update means and what it does not mean. Risks to SMMT's investment thesis continue to be a major concern for me, but the risk-tolerant could see an opportunity here. Read the full article on Seeking Alpha
새로운 내러티브 • Apr 02
Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity
Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing ivonescimab for the treatment of multiple solid tumor cancers. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 19
Future Clinical Setbacks In Phase III Programs Will Threaten Long Term Oncology Ambitions
Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing ivonescimab for cancer patients across multiple solid tumor indications. What are the underlying business or industry changes driving this perspective?Recent updates
Seeking Alpha • May 04
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary
Summary Summit Therapeutics Inc. continues its march toward potential approval in lung cancer. Recent updates put the utility of ivonescimab into question as a frontline therapy. This article is going to focus on explaining what this update means and what it does not mean. Risks to SMMT's investment thesis continue to be a major concern for me, but the risk-tolerant could see an opportunity here. Read the full article on Seeking Alpha새로운 내러티브 • Apr 02
Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity
Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing ivonescimab for the treatment of multiple solid tumor cancers. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Mar 19
Future Clinical Setbacks In Phase III Programs Will Threaten Long Term Oncology Ambitions
Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing ivonescimab for cancer patients across multiple solid tumor indications. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 05
Late Stage Oncology Footprint Will Transform This Single Asset Into A Global Cancer Franchise
Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing ivonescimab for solid tumor cancers. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 26
Summit Therapeutics: New Ivonescimab Data Raise Concerns
Summary Summit Therapeutics' share price plunged 36% after Akeso's ivonescimab data showed no statistically significant overall survival benefit versus Merck's Keytruda in the HARMONi-2 trial. Ivonescimab showed a 22% reduction in the risk of death versus Keytruda, but statistical significance was not reached after an interim analysis at 39% data maturity. Prior progression-free survival data and positive overall survival trends still point to a positive outcome in the HARMONi-2 trial. However, substantial doubts over ivonescimab and its potential benefits remain. Key upcoming catalysts include HARMONi trial results in mid-2025, additional overall survival data from HARMONi-2, and HARMONi-6 trial results from Akeso later this year. Read the full article on Seeking AlphaSeeking Alpha • Apr 12
Summit Therapeutics: Not Pharmacyclics, Not Yet
Summary Summit Therapeutics' ivonescimab shows promise but faces significant risks; HARMONi-2 results are promising but not definitive, with key questions about overall survival and applicability outside China. The CEO's recent stock moves signal confidence, but SMMT's current valuation appears overly optimistic given the uncertainties and lack of mature data. Multiple ongoing trials for ivonescimab in various cancers could provide future opportunities, but current hype may not justify the high market cap. My sentiment remains a "Sell" here due to downside risk if there is any marginal or negative data readout, either from SMMT, their partner, or any other PD1/VEGF developer. Read the full article on Seeking AlphaSeeking Alpha • Mar 28
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Summary Summit Therapeutics' ivonescimab has shown superior efficacy to ~$30bn per annum selling Keytruda in Phase 3 lung cancer trials, albeit only in Chinese patients. Summit's task is to secure approval for ivonescimab in Western markets - hence its upcoming HARMONi Phase 3 study data readout is crucial as it includes Western patients. Positive results could open up the path to a quick approval, and significantly boost Summit's valuation, while negative results could severely impact it. Seemingly, most of the patients in the HARMONi study are Chinese patients, who already showed strong results in the HARMONi-A study. Summit may be attempting to circumvent FDA rules preventing overseas studies being used in approval submissions, by adding a few Western patients to an already successful study. I have my doubts that this strategy can work. Read the full article on Seeking AlphaSeeking Alpha • Feb 24
Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Summary Summit Therapeutics Inc. established a clinical trial collaboration agreement with Pfizer to develop ivonescimab together with vedotin ADCs to target patients with NSCLC and other various types of solid tumors. Top-line data from the phase 3 HARMONi study, using ivonescimab +chemotherapy to target 2nd-line EGFR-mutant NSCLC patients, expected in mid-2025. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031. Ivonescimab + chemotherapy has already been approved in China to treat 2nd-line EGFR-mutant locally advanced or metastatic non-squamous NSCLC patients who progressed on EGFR-TKI drug. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)
Summary Summit Therapeutics' stock rose 888% since September 2023, driven by positive Phase 3 data for ivonescimab showing superior PFS vs Keytruda in NSCLC. Phase 3 HARMONi-2 trial showed 11.14 vs 5.82 months PFS benefit over Keytruda, with OS data expected in first half of 2025. Company has strong cash position ($486.9M) but faces increased burn rate with multiple Phase 3 trials ongoing. My NPV model suggests $20.5B-$29B value potential, assuming 50-60% market penetration and 2027 launch. Major risks include OS data outcomes, geographic translation of results, and complete dependence on single asset success. Read the full article on Seeking AlphaSeeking Alpha • Jan 05
The Play On Summit Therapeutics
Summary Summit Therapeutics' stock has pulled back over 40% from its all-time high due to concerns over ivonescimab's Chinese trial not being an apples-to-apples comparison. Ivonescimab, a bispecific antibody, has shown promising results in China, outperforming Merck's Keytruda in a Phase 3 trial, but faces scrutiny over trial design differences. Summit's financial health is bolstered by significant investments and private placements, providing a decent operating runway with ongoing and planned NSCLC trials. An analysis around Summit Therapeutics and how I am placing a trade on this stock is highlighted in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 02
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Summary Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III results for ivonescimab versus KEYTRUDA in first-line NSCLC are promising, but registration in the US will require completion of HARMONI-7, which has just begun recruiting. Top-line data from the HARMONi trial is expected in mid-2025, potentially leading to FDA approval with complete enrollment as of Q3. SMMT stock remains a strong buy, with excellent execution led by CEO Bob Duggan. Read the full article on Seeking AlphaSeeking Alpha • Oct 04
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Summary Summit Therapeutics Inc. may have the successor to Merck's >$25bn selling keytruda in its pipeline. Partner Akeso's data from China clinical studies shows outperformance against Merck's standard of care in NSCLC. This is no small feat — repeat this performance in US studies and Summit will have a “mega-blockbuster” on its hands/. After sensational share price gains in September, the market is more circumspect. It may be time to watch on and see how Summit's plans for US approval develop. Read the full article on Seeking AlphaSeeking Alpha • Sep 19
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summary Summit Therapeutics' ivonescimab shows improved efficacy over Merck's Keytruda in Phase III trials, targeting both PD-1 and VEGF, potentially expanding the PD-1 inhibitor market. Despite risks, Summit's promising data and significant insider investment suggest a speculative buy, with potential for major upside if FDA approval is achieved. Ivonescimab's dual mechanism could disrupt the oncology market, similar to Regeneron's Eylea, positioning Summit for substantial growth if it captures market share. With sufficient funding to complete trials and strong insider confidence, Summit is well-positioned for future success, making it a speculative buy on pullbacks. Read the full article on Seeking AlphaSeeking Alpha • Sep 09
Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Summary Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC, but regulatory and clinical hurdles remain before it can challenge the current standard of care. HARMONi-2 trial results are promising, but ivonescimab faces approval challenges in the US due to reliance on China-only trials and lack of overall survival data. SMMT's financial stability is precarious, with a cash runway of 5-6 quarters (maybe time enough to get to a phase 3 readout in their US trial). Given the high market cap and current uncertainties, it's prudent to wait for more concrete evidence of ivonescimab's superiority before investing heavily in SMMT stock. Read the full article on Seeking AlphaSeeking Alpha • Aug 03
Summit Therapeutics May Have Further Upside From Here
Summary Summit Therapeutics to release second-quarter earnings and operational update on 6 August. Analysts are bullish on Phase 3 trial results for Ivonescimab in September, with a potential de-risking of the drug's profile. The company boosted its balance sheet with a $200 million institutional capital raise and expanded licensing territories after positive Phase I and II trial results. Read the full article on Seeking AlphaSeeking Alpha • May 31
Summit Therapeutics Stock: Plunging Despite A Win?
Summary Summit Therapeutics has achieved massive market success in 2024, with a market capitalization of over $7 billion. Summit's main pipeline candidate is ivonescimab, a bispecific antibody targeting both PD-1 and VEGF. Ivonescimab has shown "decisive" progression-free survival benefit compared to Keytruda in patients with NSCLC that is PD-L1 positive. The massive valuation of SMMT means they have too much proving to do to make this a sound investment at these levels, in my opinion. Read the full article on Seeking AlphaSeeking Alpha • May 06
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
Summary Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases. Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows promise in treating non-small cell lung cancer. The company's Ivonescimab, a bispecific antibody, is supported by a partnership with Akeso. Ivonescimab targets PD-1 and VEGF pathways, potentially treating NSCLC and other cancers. Summit’s promising clinical trials, HARMONi and HARMONi-3, focus on advanced lung cancers and aim for FDA approval. SMMT is a strong buy because of ivonescimab’s potential in oncology and the company’s proven leadership under Robert Duggan. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Summary Summit's financial position is stable with adequate funds to support operations until H2 2024, despite a significant drop in cash reserves. Ivonescimab, SMMT's dual-acting compound targeting PD-1 and VEGF, shows promise in the field of oncology, particularly in non-small cell lung cancer. The success of Ivonescimab in Phase III trials is crucial for Summit's future, and investors will closely monitor clinical data and market positioning. Read the full article on Seeking AlphaSeeking Alpha • Oct 04
Summit Therapeutics slips on plans to terminate study for lead candidate
Summit Therapeutics (NASDAQ:SMMT), a biotech focused on infectious diseases, dropped ~5% pre-market Tuesday after the company announced it would discontinue a pediatric clinical trial for lead asset ridinilazole for Clostridioides difficile infection. The decision follows a Type C meeting the company conducted with the FDA in which the regulator cited the need for at least one additional registrational trial to allow a potential marketing authorization for ridinilazole. After that, the company has decided to divest ridinilazole or seek partners to advance its studies further, SMMT said in a regulatory filing on Tuesday. In December, the company said that its Phase 3 Ri-CoDIFy study for ridinilazole failed to meet the main goal in patients with C. difficile infection.Seeking Alpha • Aug 17
Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Ridinilazole failed to meet the endpoint of superiority over vancomycin in phase 3 trials. Summit Therapeutics has a preclinical antibiotic for Enterobacteriaceae, an infection where there is a clear need for novel therapeutics. Antibiotics are an extremely difficult segment of the pharmaceutical business and while novel anti-infectives are urgently needed, the company is wise to have a more broadly diversified business plan. Summary Summit Therapeutics (SMMT) reported disappointing results for their lead asset, ridinilazole which is unlikely to generate significant revenue if ever approved. The company is in early stage testing of its antibiotic which has activity against Enterobacteriaceae, a pathogen which is increasingly resistant to standard antibiotics. The company is a few years away from proof of concept human efficacy data for this asset, SMT-737. Given the difficulty of focusing on anti-infectives, the company has made a decision to expand into the microbiome and/or oncology through business development. Ridinilazole is unlikely to be widely prescribed Summit Therapeutics announced that they met with the FDA to discuss results of the CoDIFy Phase III clinical trials. The trials were pivotal trials comparing ridinilazole to vancomycin and designed to show superiority over one of the current standard of care antibiotics, vancomycin. In the clinical trials conducted to date, ridinilazole failed to show superiority over vancomycin. Summit was advised that an additional clinical trial would be required and they plan to explore this possibility. The company described the pathway as requiring "reasonable efforts." The real issue however is that fidaxomicin, an antibiotic marketed by Merck was tested and was shown to be non-inferior to vancomycin in clinical response at the end of treatment and superior to vancomycin in sustained clinical cure at 25 days post treatment. Sustained cure rates in pivotal trials were 70% and 72 % for fidaxomicin vs 57% for vancomycin at day 25. For a first episode of C. difficile infection ((CDI)), Infectious Disease Society of America ((IDSA)) now recommends a standard course or a pulsed course of fidaxomicin as the preferred choice. Fidaxomicin, which is highly effective, will likely be generically available by 2028 making ridinilazole unlikely to be widely prescribed. In addition, Acurx Pharmaceuticals (ACXP) is developing ibezapolstat, an antibiotic for CDI. A 100 percent cure rate at day 12 was observed with no recurrence at day 38 in all of the 10 patients treated in the phase 2A trial. In addition, there were no treatment discontinuations and no SAEs. One patient out of the ten treated patients reported nausea. Of the 10 treated patients in the phase 2A trial, 86% of the stool samples tested were positive for C. difficile growth at day 1 but by day 3 of treatment and at every time point thereafter, no C. difficile was detected in stool. This indicates a rapid onset and swift eradication of C. difficile. Further clinical trials are now underway but if this profile is verified in the ongoing Phase 2B testing, ibezapolstat may be a preferred drug to treat CDI. Given the competitive landscape, further development may only be logical if Summit Therapeutics can secure outside funding (potentially from BARDA) and if the clinical trial is relatively inexpensive to conduct. The Pipeline- SMT-737 Summit Therapeutics estimates there are more than a million Enterobacteriaceae infections annually. Some of these infections are increasingly resistant to standard antibiotics such as penicillins and cephalosporins. The CDC has identified carbapenem-resistant Enterobacteriaceae as an urgent threat. Carbapenems are a class of antibiotics reserved for serious infections that are administered IM or IV. Resistance to these last resort antibiotics is very concerning. SMT-737 has a unique mechanism of action which is different from existing antibiotics. IND-enabling studies are underway. In in-vitro studies (in the laboratory) SMT-737 was potent and bactericidal against multiple strains including drug resistant Enterobacteriaceae. Testing to date has been conducted in an animal model of UTI where cure of infection was observed. While this bacteria is common in the urinary tract, and UTI may be the lead indication, the drug also achieved systemic distribution and was detected in the bloodstream and lungs. Thus, it may be effective in other infections. There is a clear unmet need for novel antibiotics to treat these infections which most commonly occur in hospitalized patients. Premium pricing would certainly be warranted given there are an estimated 2500 deaths annually from drug resistant strains. Business Development Summit Therapeutics reported that, "Our intention is to expand our pipeline product portfolio in the therapeutic area of oncology and/or product offerings that are designed to work in harmony with the human gut microbiome. We intend to enact this through business development activities, including possible acquisitions and/or collaborations in addition to internal research and discovery efforts."Seeking Alpha • Aug 11
Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Summit Therapeutics press release (NASDAQ:SMMT): Q2 GAAP EPS of -$0.17. Revenue of $0.23M (+283.3% Y/Y).주주 수익률
| SMMT | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -4.8% | -4.9% | -1.0% |
| 1Y | -29.6% | 28.1% | 23.3% |
수익률 대 산업: SMMT은 지난 1년 동안 28.1%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: SMMT은 지난 1년 동안 23.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| SMMT volatility | |
|---|---|
| SMMT Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: SMMT의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: SMMT의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2003 | 265 | Bob Duggan | www.smmttx.com |
서밋 테라퓨틱스는 바이오 제약 회사로 환자, 의사, 간병인 및 사회 친화적인 의학적 치료법의 발견, 개발 및 상용화에 주력하고 있습니다. 주요 개발 후보 물질은 비소세포폐암(NSCLC) 및 대장암(CRC) 치료를 위한 항혈관신생 작용을 하는 PD-1 차단을 통한 면역 치료용 이중특이성 항체인 이보네시맙(ivonescimab)입니다. 또한 표피 성장 인자 수용체, 돌연변이, 국소 진행성 또는 전이성 비편평 비소세포폐암, 1차 전이성 비소세포폐암, 1차 절제 불가능한 전이성 CRC 환자를 대상으로 이본시맙과 화학 요법을 병용하는 3상 임상 시험을 진행 중입니다.
Summit Therapeutics Inc. 기초 지표 요약
| SMMT 기초 통계 | |
|---|---|
| 시가총액 | US$12.30b |
| 순이익 (TTM) | -US$1.21b |
| 매출 (TTM) | n/a |
0.0x
주가매출비율(P/S)-11.5x
주가수익비율(P/E)SMMT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SMMT 손익계산서 (TTM) | |
|---|---|
| 매출 | US$0 |
| 매출원가 | US$0 |
| 총이익 | US$0 |
| 기타 비용 | US$1.21b |
| 순이익 | -US$1.21b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.55 |
| 총이익률 | 0.00% |
| 순이익률 | 0.00% |
| 부채/자본 비율 | 0% |
SMMT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 00:00 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Summit Therapeutics Inc.는 27명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Etzer Darout | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Timothy Chiang | BTIG |